Research and laboratory use only. Not for human consumption.
Research Use Only
This website contains information about compounds and materials intended strictly for laboratory and scientific research purposes.
By entering this website, you acknowledge that the information and materials presented are intended for research and educational purposes only.
Kisspeptin
Kisspeptins are naturally occurring neuropeptides encoded by the KISS1 gene. They act through the KISS1 receptor to regulate gonadotropin-releasing hormone signalling and are central to puberty, reproductive hormone secretion and the hypothalamic-pituitary-gonadal axis.
What is Kisspeptin?
Kisspeptin refers to a family of biologically active peptides produced from the protein encoded by the KISS1 gene.
The peptides bind to a G-protein-coupled receptor now called KISS1R, which was historically known as GPR54.
Kisspeptin signalling is now recognised as one of the principal upstream regulators of human reproductive endocrinology.
Within the hypothalamus, kisspeptin neurons stimulate neurons that release gonadotropin-releasing hormone (GnRH) .
GnRH subsequently acts on the anterior pituitary to stimulate secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH) .
Through this pathway, kisspeptin participates in puberty, menstrual-cycle regulation, ovulation, sex-steroid production and reproductive function in both males and females.
Why is it called Kisspeptin?
The name has an unusual history that predates discovery of its central reproductive role.
Compound Summary
The KISS1 gene was originally identified during research into suppression of tumour metastasis rather than reproductive biology.
Its peptide product was initially called metastin because of its association with metastasis-suppressing activity.
The term kisspeptin subsequently became widely adopted for the family of KISS1-derived peptides.
Research then revealed that the receptor GPR54 was the receptor for kisspeptin and that disruption of this signalling system caused profound reproductive dysfunction.
This discovery transformed kisspeptin from a peptide associated mainly with cancer biology into one of the most important recognised regulators of the reproductive endocrine axis.
Kisspeptin is not just one peptide.
Processing of the KISS1 precursor produces several biologically active peptides sharing a common C-terminal sequence.
Kisspeptin-54
The 54-amino-acid form is commonly described as the major circulating kisspeptin isoform in humans and has been extensively investigated in reproductive clinical studies.
Kisspeptin-10
Kisspeptin-10 is the shortest commonly studied active fragment and contains the C-terminal sequence required for activation of KISS1R.
Other Processed Forms
Kisspeptin-14 and kisspeptin-13 have also been identified. These peptides share the biologically important C-terminal region of the KISS1-derived sequence.
How does Kisspeptin control reproductive hormones?
Kisspeptin sits upstream of the classical hypothalamic-pituitary-gonadal endocrine pathway.
KISS1-derived peptides are produced by specialised neurons and other tissues.
Kisspeptin activates its G-protein-coupled receptor on GnRH neurons.
Hypothalamic GnRH secretion increases.
Pituitary gonadotropin secretion is stimulated.
Ovulation, gametogenesis and sex-steroid signalling are regulated downstream.
Why is Kisspeptin important?
The KISS1/KISS1R system is involved in several fundamental stages of reproductive function.
Kisspeptin signalling is a key component of the neuroendocrine activation required for normal pubertal development.
Kisspeptin neurons contribute to the generation and regulation of pulsatile GnRH secretion.
Kisspeptin participates in mechanisms associated with the preovulatory GnRH and LH surge.
Kisspeptin stimulation can increase LH, FSH and downstream gonadal steroid signalling in males.
Genetics helped reveal the importance of Kisspeptin.
One of the strongest demonstrations of the biological importance of kisspeptin signalling came from human genetic studies.
Loss-of-function mutations affecting KISS1R were found in individuals with hypogonadotropic hypogonadism.
In this condition, insufficient stimulation of the reproductive endocrine axis results in impaired pubertal development and reproductive function.
These observations demonstrated that intact kisspeptin receptor signalling is necessary for normal activation of the human hypothalamic-pituitary-gonadal axis.
Conversely, activating alterations in this signalling pathway have also been associated with abnormally early reproductive-axis activation, further supporting its role in pubertal timing.
Kisspeptin-54 and IVF research
One of the most developed clinical research areas involves using kisspeptin-54 to stimulate an endogenous GnRH/LH surge during assisted reproduction.
Kisspeptin-54 triggered oocyte maturation
A clinical study evaluated kisspeptin-54 in 53 women undergoing IVF treatment.
Oocyte maturation occurred following the investigated doses, and fertilisation and embryo transfer subsequently took place in the majority of participants.
Women at high risk of OHSS
A Phase 2 trial evaluated kisspeptin-54 in 60 women considered at high risk of ovarian hyperstimulation syndrome during IVF.
Oocyte maturation occurred in the large majority of participants, and no woman in the study developed moderate, severe or critical OHSS.
Second-dose Kisspeptin research
A randomized Phase 2 study investigated whether extending LH exposure with a second kisspeptin-54 administration could improve oocyte maturation.
IVF research does not mean general approval
These studies demonstrate meaningful human reproductive pharmacology, but kisspeptin remains a research compound in this context.
What else has Kisspeptin been studied for?
Human research has examined whether exogenous kisspeptin can stimulate reproductive hormone secretion in women with hypothalamic reproductive suppression.
Studies in men have examined LH, testosterone and GnRH-axis responses following kisspeptin exposure.
Kisspeptin biology is relevant to research into delayed puberty, precocious puberty and congenital hypogonadotropic hypogonadism.
Researchers have investigated kisspeptin responses as a potential method for evaluating functional capacity of the hypothalamic reproductive axis.
How strong is the evidence?
Kisspeptin has a considerably stronger human physiological evidence base than many experimental peptides, but clinical applications remain under investigation.
The KISS1/KISS1R pathway is firmly established as a major regulator of human reproductive endocrinology.
Multiple human studies demonstrate strong effects on GnRH-dependent LH and FSH secretion.
Phase 2 studies have demonstrated the ability of kisspeptin-54 to trigger oocyte maturation in controlled clinical settings.
Kisspeptin itself does not currently have a broad approved therapeutic indication.
What is known about human safety?
Human reproductive studies provide useful short-term safety information, but they do not establish the safety of long-term or uncontrolled use.
Controlled Clinical Exposure
Kisspeptin-54 has been administered to participants in carefully controlled reproductive-endocrinology studies.
These studies provide evidence that kisspeptin can produce predictable endocrine responses in selected research populations.
Long-Term Evidence
The long-term safety of sustained or repeated kisspeptin stimulation outside controlled clinical research remains much less established.
Manipulation of the GnRH/LH/FSH axis has potentially significant endocrine consequences and should not be interpreted as a trivial biological intervention.
What should not be assumed?
Where does Kisspeptin research stand today?
Kisspeptin is not a speculative peptide with only laboratory evidence. Its role in the reproductive endocrine system is supported by human genetics, physiology and controlled clinical research.
The KISS1/KISS1R system is firmly established as an upstream regulator of GnRH secretion and therefore of LH and FSH release.
Human clinical studies have demonstrated that exogenous kisspeptin-54 can stimulate reproductive-hormone secretion and trigger oocyte maturation during IVF treatment.
Despite this substantial evidence base, kisspeptin remains an investigational therapeutic strategy rather than a broadly approved reproductive medicine.
Current scientific interest continues to include fertility treatment, safer approaches to assisted reproduction, hypothalamic amenorrhoea, pubertal disorders and reproductive-axis diagnostics.
Kisspeptin research at a glance.
The gene was initially characterized in cancer biology because of its association with suppression of tumour metastasis.
The KISS1-derived peptide family was linked to the receptor now known as KISS1R.
Loss-of-function mutations affecting GPR54/KISS1R were associated with hypogonadotropic hypogonadism.
Clinical research demonstrated successful oocyte maturation during IVF following kisspeptin-54 administration.
Studies investigated kisspeptin in women at high risk of OHSS and examined optimization of the kisspeptin-triggered LH response.
Kisspeptin remains an important research target for understanding and potentially manipulating the human reproductive endocrine axis.
Selected references.
Key scientific publications covering KISS1 biology, reproductive endocrine signalling and human kisspeptin research.
Scientific & Educational Information
This profile is provided for educational and scientific purposes. Kisspeptin is a naturally occurring reproductive signalling peptide family with established physiological roles and ongoing human clinical research. Discussion of GnRH signalling, fertility, puberty, IVF, LH, FSH or other biological effects describes scientific research and should not be interpreted as medical advice, fertility treatment guidance, dosing advice or instructions for human use.
Continue exploring peptide science.
Browse additional compound profiles covering molecular biology, mechanisms of action, human research, development status and regulatory evidence.
Explore Peptide Profiles